Speedel Seeks Information On Tekturna Manufacturing Costs From Novartis
This article was originally published in The Pink Sheet Daily
Executive Summary
Basel, Switzerland firm maintains its marketing partner is withholding cost-of-goods data that could translate into more revenues for Speedel.
You may also be interested in...
Speedel CEO Alice Huxley: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Exec discusses Speedel’s other mid-stage pipeline candidates, the firm’s relationship with Novartis and business development going forward.
Speedel CEO Alice Huxley: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Exec discusses Speedel’s other mid-stage pipeline candidates, the firm’s relationship with Novartis and business development going forward.
Novartis’ Tekturna Is First Renin Inhibitor Approved For Hypertension
The first-in-class drug will launch later in March.